Erika Hamilton: Capecitabine Improves Outcomes for Residual Disease Beyond CREATE-X Trial
Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on X about a paper by A. Strahan et al. published on ESMO Journals:
“Practice affirming. Adjuvant capecitabine for residual disease after adjuvant chemo improves outcomes.
Reassuring this is true in a real world data set and not just the CREATE-X trial. Interestingly only half receive adjuvant therapy.”
Title: Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy
Authors: A. Strahan, Q. Jin, A.S. Raghavendra, D.B. Zakon, M. Grimm, M.E. Hughes, M. Cherian, J. Vincuilla, T. Parker, P. Tarantino, K.C.C. Johnson, E.A. Mittendorf, T.A. King, V. Valero, D. Tripathy, S.M. Tolaney, N. Tayob, N.U. Lin, D.G. Stover, C.H. Barcenas, A.C. Garrido-Castro
Read the full article.
More posts featuring Erika Hamilton on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023